| Project | Target | Indication | Development Stage |
|---|---|---|---|
| AZB101 | TYK2 | Autoimmune Disease | Candidate discovery in progress |
-
Mechanism of Action
AZB101 is designed to selectively target and inhibit TYK2-JH2, a mechanism linked to numerous autoimmune disorders, such as psoriasis.
-
Technical Advantage
· AZB101 is a highly selective kinase inhibitor for TYK2-JH2.
· AZB101 is being developed to be best-in-class with fewer side effects like JAK inhibitors.
· AZB101 can be applied to a wide range of indications, including several immune-mediated diseases other than psoriasis.
